AbbVie Stock - analyst consensus and long-term drivers in focus
20.06.2026 - 19:42:24 | ad-hoc-news.de
Edited by ad hoc news Long-Term & Business-Model Desk. Verified prior to publication on 06/20/2026, 19:41 CET. Details in the imprint.
AbbVie (US00287Y1091) remains one of the largest US biopharma names with a market value well above $300 billion. With no fresh earnings release or major regulatory filing this weekend, the spotlight turns to what analysts expect and how durable AbbVie's long-term cash flows look.
All news and data on AbbVie stock
Key figures, news and regulatory filings provide important context for how AbbVie is positioned in global pharmaceuticals.
What analysts are pricing in
According to recent market data, AbbVie stock trades around $216 per share on the New York Stock Exchange, implying a market cap close to $382 billion based on the latest quote snapshots. Several data providers classify the consensus view on the stock as a "Buy" rating overall.
One aggregation of analyst estimates cites an average 12-month price target of roughly $253 per share, indicating mid-teens upside from the latest trading level. That same overview shows a dividend yield of just above 3%, underlining AbbVie's continued role as an income name in large-cap pharma.
Long-term profile and key risks
AbbVie remains heavily exposed to immunology drugs and oncology therapies, with flagship products still generating high cash flows even as some face rising competition. The firm also invests steadily in research and development to defend its pipeline and offset patent expiries, a central theme in most long-term debates on the stock.
Net-net, long-term investors often weigh AbbVie's predictable cash flows and dividend track record against the need for new blockbusters in immunology and oncology. That trade-off drives much of the spread in analyst price targets and justifies the close focus on upcoming clinical and regulatory milestones.
How the company makes money
AbbVie generates the bulk of its revenue from branded prescription medicines in immunology, oncology, neuroscience and aesthetics, including its well-known immunology therapy Humira and follow-on products such as Skyrizi and Rinvoq. The business model centers on patent-protected therapies, pricing power and a broad global commercial footprint.
Where the stock trades today
The shares of AbbVie (US00287Y1091) trade on the New York Stock Exchange at $216.49 as of 06/18/2026, 16:00 ET.
Key facts on AbbVie stock
- Company: AbbVie Inc.
- ISIN: US00287Y1091
- WKN: A1J84E
- Ticker: ABBV
- Venue: NYSE
- Price (as of 06/18/2026, 16:00 ET): 216.49 USD
- Market cap: 382.56 billion USD (as of 06/18/2026)
- Sector / Industry: Health Care / Pharmaceuticals & Biotechnology
- Index membership: S&P 500
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
